Your browser is no longer supported. Please, upgrade your browser.
Settings
BMY Bristol-Myers Squibb Company daily Stock Chart
BMY [NYSE]
Bristol-Myers Squibb Company
IndexS&P 500 P/E29.22 EPS (ttm)2.36 Insider Own0.10% Shs Outstand1.64B Perf Week9.98%
Market Cap112.90B Forward P/E17.71 EPS next Y3.89 Insider Trans-9.27% Shs Float1.63B Perf Month11.53%
Income3.91B PEG2.42 EPS next Q0.84 Inst Own72.40% Short Float0.76% Perf Quarter12.92%
Sales20.78B P/S5.43 EPS this Y-10.90% Inst Trans1.17% Short Ratio1.74 Perf Half Y21.47%
Book/sh7.18 P/B9.60 EPS next Y18.57% ROA3.00% Target Price64.86 Perf Year27.04%
Cash/sh4.16 P/C16.57 EPS next 5Y12.05% ROE7.20% 52W Range51.56 - 69.44 Perf YTD12.53%
Dividend1.60 P/FCF68.72 EPS past 5Y15.30% ROI20.20% 52W High-0.69% Beta0.95
Dividend %2.32% Quick Ratio1.40 Sales past 5Y3.30% Gross Margin71.50% 52W Low33.75% ATR1.92
Employees23700 Current Ratio1.60 Sales Q/Q3.90% Oper. Margin25.20% RSI (14)74.14 Volatility2.83% 2.85%
OptionableYes Debt/Eq0.68 EPS Q/Q-34.20% Profit Margin4.80% Rel Volume1.50 Prev Close68.98
ShortableYes LT Debt/Eq0.59 EarningsFeb 05 BMO Payout261.40% Avg Volume7.13M Price68.96
Recom2.30 SMA208.68% SMA5010.33% SMA20015.65% Volume10,547,419 Change-0.03%
Feb-15-18Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-30-17Upgrade SunTrust Hold → Buy
Oct-16-17Downgrade Jefferies Buy → Hold
Sep-12-17Downgrade Hilliard Lyons Long-term Buy → Neutral
Dec-19-16Upgrade Jefferies Hold → Buy
Oct-28-16Reiterated Deutsche Bank Hold $59 → $52
Sep-09-16Reiterated Barclays Equal Weight $75 → $65
Aug-11-16Downgrade Berenberg Buy → Hold
Aug-08-16Reiterated Deutsche Bank Hold $68 → $62
Aug-08-16Downgrade Credit Suisse Outperform → Neutral $63
Aug-05-16Downgrade Morgan Stanley Overweight → Equal-Weight
May-23-16Initiated Hilliard Lyons Neutral
Apr-29-16Reiterated UBS Buy $73 → $80
Apr-29-16Reiterated Barclays Equal Weight $70 → $75
Apr-06-16Initiated Societe Generale Sell $48
Jan-22-16Upgrade Berenberg Hold → Buy
Dec-02-15Upgrade Guggenheim Neutral → Buy
Dec-01-15Reiterated Barclays Equal Weight $55 → $70
Aug-24-15Upgrade Piper Jaffray Underweight → Neutral
Jun-17-15Initiated Piper Jaffray Underweight $60
Feb-18-18 02:16PM  Benzinga's Bulls & Bears Of The Week: Bristol-Myers, GE, Target, Under Armour And More Benzinga
Feb-16-18 04:58PM  With A -77.41% Earnings Drop Lately, Did Bristol-Myers Squibb Company (NYSE:BMY) Underperform Its Industry? Simply Wall St.
04:57PM  BMY INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Bristol-Myers Squibb Company Business Wire
03:45PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bristol-Myers Squibb Company - BMY ACCESSWIRE
10:55AM  3 Reasons Pfizer May Want to Buy Bristol-Myers Squibb TheStreet.com
09:23AM  Nektar, Bristol-Myers Tie-Up for Cancer Combos Drives Stock (Revised) Zacks
08:56AM  Bristol-Myers Squibb (BMY) in Focus: Stock Moves 5.6% Higher Zacks
06:08AM  Better Buy: Exelixis, Inc. vs. Bristol-Myers Squibb Motley Fool
Feb-15-18 08:04PM  Bristol-Myers 'Is Back' and Could Soar Another 14% TheStreet.com +5.55%
04:02PM  These Were the 3 Hottest Stories on Wall Street Thursday TheStreet.com
03:40PM  Wall Street Is in the Green GuruFocus.com
03:09PM  Incyte (INCY) Beats on Q4 Revenues on Strong Jakafi Sales Zacks
01:26PM  Stocks Try To Extend Win Streak As Dow Tests This Key Level Investor's Business Daily
11:41AM  Nektar, Bristol-Myers Tie-Up for Cancer Combos Drives Stock Zacks
09:38AM  Morgan Stanley Targets New All-Time High For Bristol-Myers, Upgrades To Overweight Benzinga
08:40AM  Valentines Day deal is true love for Nektar and Bristol-Myers MarketWatch
08:16AM  Rock and Roll: Bristol-Myers Squibb Is Breaking Out TheStreet.com
Feb-14-18 05:22PM  SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Bristol-Myers Squibb Company Business Wire
05:16PM  This Megadeal Caused Nektar Therapeutics' 11% Spike Today Motley Fool
01:43PM  Bristol-Myers inks $1.85 billion cancer drug deal CNBC Videos
01:15PM  IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Bristol-Myers Squibb Company ACCESSWIRE
12:25PM  Nektar Shares Surge on Bristol-Myers Collaboration TheStreet.com
10:57AM  Bristol-Myers to pay $1.85 billion in cancer deal with Nektar Reuters
10:55AM  Bristol-Myers to pay $1.85 bln in cancer deal with Nektar Reuters
09:28AM  Stocks to Watch: Chipotle, Metlife, AT&T, Netflix, Facebook, Hilton, Bristol-Myers, Bunge, Fossil The Wall Street Journal
07:46AM  [$$] Bristol-Myers Squibb, Nektar to Partner on Cancer Therapy The Wall Street Journal
07:24AM  Nektar's $2.8 Billion Licensing Pact Leaves Options Open Bloomberg
07:21AM  Bristol-Myers and Nektar Therapeutics to jointly develop cancer treatments MarketWatch
07:00AM  Bristol-Myers To Pay Largest Fee In Biotech History For Nektar Cancer Drug Forbes
06:59AM  Bristol-Myers Squibb and Nektar Therapeutics Announce Global Development & Commercialization Collaboration for Nektars CD122-biased Agonist, NKTR-214 Business Wire
Feb-13-18 11:41AM  INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Bristol-Myers Squibb Company Business Wire
Feb-12-18 07:30PM  SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Bristol-Myers Squibb Company (NYSE: BMY) To Contact Brower Piven Before The Lead Plaintiff Deadline GlobeNewswire
04:20PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bristol-Myers Squibb Company - BMY PR Newswire
03:39PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Bristol-Myers Squibb Company Business Wire
10:15AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Bristol-Myers Squibb Company (BMY) & Lead Plaintiff Deadline: April 10, 2018 PR Newswire
Feb-09-18 07:22PM  Glancy Prongay & Murray LLP Files a Securities Class Action on Behalf of Bristol-Myers Squibb Company Investors (BMY) Business Wire
11:00AM  Solid Q4 Earnings Drive Pharma ETF Outlook Zacks
Feb-08-18 06:59AM  Bristol-Myers Squibb to Take Part in Leerink 7th Annual Global Healthcare Conference Business Wire
Feb-07-18 03:44PM  Bristol-Myers Squibb Company -- Moody's affirms Bristol-Myers at A2; revises outlook to stable Moody's
07:30AM  Wired News Bristol-Myers Squibbs Phase-3 CheckMate-227 Study Met its Co-Primary Endpoint ACCESSWIRE
Feb-06-18 04:18PM  Bristol Continues 2-Day Plunge Amid Debate On Merck-Rivaling Combo Investor's Business Daily
10:19AM  Bristol-Myers' Opdivo/Yervoy Combo Positive in Cancer Study Zacks
09:09AM  Bristol-Myers touts lung cancer breakthrough, but critics cry foul MarketWatch
Feb-05-18 06:07PM  More Questions Than Answers For Bristol-Myers Forbes
04:20PM  Bristol-Myers Squibb Dives Despite Strong Earnings, Opdivo Data Investor's Business Daily
04:18PM  Dow Tumbles 1,175 Points, Largest Single-Day Point Loss Ever TheStreet.com
03:45PM  Wall Street Wants Details About Lung Cancer Drug GuruFocus.com
02:26PM  Bristol-Myers Wins, But Not in an Eagles-Super-Bowl Way Bloomberg
02:24PM  Bristol-Myers (BMY) Beats on Q4 Earnings, Eliquis Impresses Zacks
01:30PM  Earnings movers & a takeover target in the trader blitz CNBC Videos
01:14PM  Bristol-Myers' positive cancer data still lags Merck Reuters
01:04PM  3 Things to Really Like About Bristol-Myers Squibb's Q4 Earnings Results Motley Fool
11:17AM  Bristol-Myers Squibb Company (BMY) Q4 2017 Earnings Conference Call Transcript Motley Fool
11:09AM  Bristol Myers Beats Estimates, Gives Positive News on Lung Cancer Drugs TheStreet.com
10:35AM  Bristol-Myers Squibb Earnings, Trial Results Not Enough to Please Investors 24/7 Wall St.
10:30AM  Genprex Launch IPO For Trials Of New Gene Therapy Lung Cancer Treatment Forbes
09:35AM  Stocks to Watch: Wells Fargo, Apple, Qualcomm, Bristol-Myers, Boeing, Equifax, Bunge, Arconic The Wall Street Journal
09:33AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
08:10AM  Bristol-Myers (BMY) Q4 Earnings Beat Estimates Zacks
07:38AM  Bristol-Myers Lung-Cancer Data a `Mixed Bag' in Key Trial Bloomberg
07:31AM  S&P 500 Futures Tumble As Sell-Off Continues; Broadcom Makes 'Final' Qualcomm Bid Investor's Business Daily
07:24AM  Bristol-Myers surges 5.6% on advanced lung cancer trial results, Q4 earnings MarketWatch
07:21AM  Bristol-Myers reports 4Q loss Associated Press
06:59AM  Pivotal Phase 3 CheckMate -227 Study Demonstrates Superior Progression-Free Survival (PFS) with the Opdivo Plus Yervoy Combination Versus Chemotherapy in First-Line Non-Small Cell Lung Cancer (NSCLC) Patients with High Tumor Mutation Burden (TMB) Business Wire
06:59AM  Bristol-Myers Squibb Reports Fourth Quarter and Full Year Financial Results Business Wire
Feb-02-18 04:30PM  Biotech stocks hold up amid market sell-off CNBC Videos
04:19PM  Dow's Merck Lags On Sales, But Earnings, 2018 Outlook Top Investor's Business Daily
Feb-01-18 08:35AM  Should You Sell Bristol-Myers Squibb (BMY) Before Earnings? Zacks
Jan-31-18 10:34AM  Will Bristol-Myers' (BMY) Q4 Earnings Exceed Expectations? Zacks
Jan-26-18 10:32AM  Pfizer: Analysts Ratings and Recommendations for 4Q17 Market Realist
09:15AM  Infinity Provides Update on Lead Candidate, Issues 2018 View Zacks
07:33AM  What Are Pfizers Positive Growth Contributors? Market Realist
Jan-25-18 04:05PM  Five Prime Therapeutics Announces $25 Million Payment by Bristol-Myers Squibb for Cabiralizumab Development Milestone GlobeNewswire
12:40PM  Pfizer in 4Q17: Revenue Estimates Based on Geographies Market Realist
09:00AM  Tasigna Could Boost Novartiss Revenue Growth in 2018 Market Realist
Jan-24-18 09:01AM  A Look at Nektar Therapeutics Financial Performance Market Realist
07:35AM  Novartiss Crizanlizumab Demonstrates Positive Results in Trials Market Realist
07:33AM  Nektars Deals: Daiichi Sankyo, Ophthotech, Bristol-Myers Squibb Market Realist
Jan-23-18 03:39PM  How Is Novartiss Kymriah Positioned for 2018? Market Realist
11:37AM  Analysts Ratings for Nektar Therapeutics in January 2018 Market Realist
09:44AM  Seattle Genetics' Adcetris Gets EU Nod for Label Expansion Zacks
Jan-22-18 10:22AM  Bristol-Myers (BMY) Reports Data from CheckMate-142 Study Zacks
08:17AM  Whom Will Pfizer Buy in 2018? Motley Fool
07:32AM  Merck & Co.s Cardiovascular and Immunology Products in 3Q17 Market Realist
07:31AM  What Analysts Recommend for Bristol-Myers Squibb in January 2018 Market Realist
06:59AM  European Commission Approves Bristol-Myers Squibbs Yervoy (ipilimumab) for Treatment of Pediatric Patients 12 Years and Older with Unresectable or Metastatic Melanoma Business Wire
Jan-21-18 12:25PM  Merck leaps past rivals with latest lung cancer drug results MarketWatch
Jan-20-18 02:03PM  Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Demonstrates Clinical Activity in Previously Treated Patients with dMMR or MSI-H Metastatic Colorectal Cancer Business Wire
Jan-19-18 03:17PM  BMY INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of Bristol-Myers Squibb Company Investors Business Wire
11:05AM  Johnson & Johnsons Pharmaceutical Segment: 4Q17 Estimates Market Realist
10:34AM  Merck & Co.s Diabetes Products in 3Q17 Market Realist
10:32AM  Opdivo Could Be Long-Term Growth Driver for Bristol-Myers Squibb Market Realist
09:03AM  What to Expect from Bristol-Myers Squibbs Yervoy in 2018 Market Realist
09:01AM  Analysts Recommendations for Amgen in January 2018 Market Realist
08:05AM  Johnson & Johnsons 4Q17 Earnings on January 23: What to Expect Market Realist
08:02AM  Pharma And Biotech Dividend Stocks That Will Add Value To Your Portfolio Simply Wall St.
07:34AM  Keytruda: Merck & Co.s Immuno-Oncology Blockbuster Drug Market Realist
07:33AM  How Is Bristol-Myers Squibbs Sprycel Positioned for 2018? Market Realist
Jan-18-18 05:51PM  Bear Stearns Commercial Mortgage Securities Trust 2007-PWR15 -- Moody's Affirms Four Classes of BSCMS 2007-PWR15 Moody's
02:28PM  Mercks & Co.s Valuation in January 2018 Market Realist
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in the various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection. Its products include Opdivo, a biological product for the treatment of anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in atrial fibrillation and the prevention and treatment of venous thromboembolic disorders; Orencia, a biological product that targets adult patients with active rheumatoid arthritis and prostate-specific antigen; and Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia. The company's products also comprise Yervoy, a monoclonal antibody for the treatment of adults and pediatric patients with unresectable or metastatic melanoma; Empliciti, a human monoclonal antibody for the treatment of multiple myeloma; Baraclude, a potent and selective inhibitor of the hepatitis B virus; Sustiva, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV and bulk efavirenz; Reyataz, a protease inhibitor for the treatment of HIV and combination therapy Evotaz; Daklinza, an oral small molecule NS5A replication complex inhibitor for the treatment of hepatitis C virus (HCV); and Sunvepra, an oral small molecule for the treatment of HCV. It sells products to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. Bristol-Myers Squibb Company has a research partnership with Sirenas; and a strategic development and commercialization collaboration agreement with Nektar Therapeutics. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Samuels Theodore R. IIDirectorDec 15Buy62.304,000249,18722,000Dec 18 04:21 PM
Lynch Thomas J. Jr.EVP & Chief Scientific OfficerDec 12Sale63.245,300335,1729,251Dec 13 05:31 PM
LEUNG SANDRAEVP, General CounselDec 04Option Exercise22.14156,5823,466,725584,373Dec 05 06:15 PM
LEUNG SANDRAEVP, General CounselDec 04Sale63.37156,5829,922,601427,791Dec 05 06:15 PM
Bancroft Charles AEVP & Chief Financial OfficerDec 02Option Exercise0.006,4010267,770Dec 05 06:15 PM
Elicker John ESVP, Public Affairs & IRNov 01Option Exercise0.00494068,166Nov 03 04:32 PM
Caldarella Joseph CSVP & ControllerSep 06Sale60.009,340560,40046,297Sep 08 04:31 PM
Nielsen AnneChief Compliance & Ethics OffSep 03Option Exercise0.001,594038,811Sep 06 04:46 PM
Samuels Theodore R. IIDirectorAug 02Buy55.946,000335,62218,000Aug 03 05:08 PM
Gordon MurdoEVP, Chief Commercial OfficerAug 01Option Exercise0.001,510028,751Aug 03 05:07 PM
Lynch Thomas J. Jr.EVP & Chief Scientific OfficerMay 14Option Exercise0.0014,551014,551Jun 08 04:51 PM
Caforio GiovanniChairman and CEOMay 05Option Exercise0.008,0400180,458May 09 04:32 PM
ANDREOTTI LAMBERTODirectorApr 07Sale53.2217,000904,791935,571Apr 10 05:09 PM
ANDREOTTI LAMBERTODirectorApr 06Sale53.2917,000905,964952,571Apr 10 05:09 PM
JUDGE ANN POWELLSVP, Global Human ResourcesApr 01Option Exercise0.001,554044,125Apr 04 07:17 PM
ANDREOTTI LAMBERTODirectorMar 28Sale56.2017,000955,369969,112Mar 29 06:19 PM
ANDREOTTI LAMBERTODirectorMar 27Sale56.1417,000954,451986,112Mar 29 06:19 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 17Sale56.495,000282,47021,483Mar 21 04:35 PM
Caldarella Joseph CSVP & ControllerMar 15Sale57.298,096463,77955,637Mar 22 06:20 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 14Sale56.7515,000851,22026,483Mar 16 04:37 PM
Caforio GiovanniChief Executive OfficerMar 10Option Exercise0.0087,6040199,229Mar 14 08:32 PM
Blin EmmanuelSVP, Chief Strategy OfficerMar 10Option Exercise0.0013,275023,690Mar 14 08:32 PM
Cuss Francis MEVP & CSOMar 10Option Exercise0.0066,7260346,770Mar 14 08:33 PM
LEUNG SANDRAEVP, General CounselMar 10Option Exercise0.0065,4240451,862Mar 14 08:33 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 10Option Exercise0.0031,7210119,772Mar 14 08:31 PM
Gordon MurdoEVP, Chief Commercial OfficerMar 10Option Exercise0.0025,592035,898Mar 14 08:31 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 10Option Exercise0.0087,3240289,293Mar 14 08:31 PM
Nielsen AnneChief Compliance & Ethics OffMar 10Option Exercise0.0013,696041,215Mar 14 08:30 PM
ANDREOTTI LAMBERTODirectorMar 10Option Exercise0.00102,17401,060,105Mar 14 08:30 PM
JUDGE ANN POWELLSVP, Global Human ResourcesMar 10Option Exercise0.0031,513052,546Mar 14 08:29 PM
Elicker John ESVP, Public Affairs & IRMar 10Option Exercise0.0018,799073,284Mar 14 08:29 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 10Option Exercise0.0033,271051,898Mar 14 08:30 PM
Caldarella Joseph CSVP & ControllerMar 10Option Exercise0.0015,484068,911Mar 14 08:29 PM
LEUNG SANDRAEVP, General CounselMar 06Sale57.0292,4055,268,563395,658Mar 07 04:39 PM
LEUNG SANDRAEVP, General CounselMar 03Option Exercise27.01116,1003,135,861488,063Mar 07 04:39 PM
Bancroft Charles AEVP & Chief Financial OfficerFeb 28Option Exercise27.0122,598610,372212,516Mar 01 04:47 PM
Samuels Theodore R. IIDirectorFeb 27Buy56.7712,000681,24012,000Mar 01 04:47 PM